FDA's guidance on clinical trials good, but issues will arise- analyst

Odonate

19/03/2020 12:04

** After FDA on Wednesday said http://bit.ly/2Wrwd88 it
recognized conducting clinical trials may be affected due to the
COVID-19 pandemic, Jefferies indicates impact, especially on
small to mid-cap companies where it's their only drug or only
study     
    ** Brokerage says investors must prepare for a scenario
where a 1-2 month potential pause is very likely and trials
requiring hospital admissions could have some impact
    ** Sees FDA's announcement as generally good, but flags
issues to arise; says FDA will soon have to address how the
current COVID-19 situation will impact upcoming advisory
committee meetings and FDA approvals
    ** Says Akero Therapeutics  AKRO.O , Intercept
Pharmaceuticals  ICPT.O , Kodiak Sciences  KOD.O  and Odonate
Therapeutics  ODT.O  could see minimal impact or timelines
pushed by 1-3 months; in the worst case scenario, trials could
be hugely interrupted due to missed biopsies and results

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))